Summary: <p>This week <em>The Lancet</em> formally published the largest ever randomized trial of thrombolytics for acute stroke. Hands are wringing, teeth are gnashing, and department heads are fighting.</p> <p>It is the biggest, baddest controversy in our field: Do clot-busters benefit stroke patients?</p> <p>Let's do this.</p>
